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Background: Malignant melanoma has an increasing incidence rate and the metastatic disease is notoriously
resistant to standard chemotherapy. Loss of cell cycle checkpoints is frequently found in many cancer types and
makes the cells reliant on compensatory mechanisms to control progression. This feature may be exploited in
therapy, and kinases involved in checkpoint regulation, such as Wee1 and Chk1/2, have thus become attractive
therapeutic targets.
Methods: In the present study we combined a Wee1 inhibitor (MK1775) with Chk1/2 inhibitor (AZD7762) in
malignant melanoma cell lines grown in vitro (2D and 3D cultures) and in xenografts models.
Results: Our in vitro studies showed that combined inhibition of Wee1 and Chk1/2 synergistically decreased viability
and increased apoptosis (cleavage of caspase 3 and PARP), which may be explained by accumulation of DNA-damage
(increased expression of γ-H2A.X) - and premature mitosis of S-phase cells. Compared to either inhibitor used as single
agents, combined treatment reduced spheroid growth and led to greater tumour growth inhibition in melanoma
xenografts.
Conclusions: These data provide a rationale for further evaluation of the combination of Wee1 and Chk1/2
inhibitors in malignant melanoma.
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Malignant melanoma is the deadliest form of skin can-
cer, in addition to having one of the most increasing
incidence rates of all cancer forms [1]. Although curable
by surgical excision at an early stage, patients diagnosed
with metastatic melanoma (stage IV) have had a median
survival of 6–10 months [2]. Despite recent year’s advances
leading to new treatment options such as Ipilimumab,
Vemurafenib, Trametinib and Dabrafenib, there are still
no curative treatment alternatives for the majority of
the patients with advanced disease [3, 4].
In response to DNA-damage, the dividing cell is
arrested through activation of checkpoint mechanisms* Correspondence: vivi.ann.florenes@radiumhospitalet.no
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Hospital, N-0310 Oslo, Norway
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© 2015 Magnussen et al.in order to allow time for DNA-repair to be completed.
If the damage is too severe, apoptosis or senescence is
induced to ensure that unrepaired DNA-damage is not
passed on to future generations of cells. Loss of check-
point mechanisms is frequently found in cancer, a trait
which can be exploited in cancer therapy. Wee1 is a kin-
ase involved in checkpoint regulation that in response to
DNA-damage or replication stress can halt the cell cycle
progression in S- and G2 phases by adding inhibitory
phosphorylations (Tyr15) on cyclin-dependent kinases
CDK2 and CDK1, respectively [5]. In our previous study
we found that Wee1 was up-regulated in human melano-
mas as compared to benign nevi, and that high expression
of Wee1 was associated with poor disease-free survival
[6]. Likewise, over-expression of Wee1 (protein and/or
mRNA) has been reported in osteosarcoma, glioblastoma
and ovarian- and vulvar squamous cell carcinomas, thus
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[6–10]. Furthermore, targeting Wee1, either by siRNA
mediated silencing or inhibitors, has in several studies,
including ours, been shown to lead to increased DNA-
damage and apoptosis [6, 11, 12].
Although mono-targeting of Wee1 has shown anti-
tumour effect in some cancer cell lines, a stronger effect
has been observed when combining Wee1 inhibitors with
for instance DNA-damaging agents, Heath Shock Protein
90 inhibitors and more recently inhibitors of other cell
cycle regulatory proteins such as Chk1/2 [13–16]. The
Chk1/2 kinases are key regulators of DNA-damage sur-
veillance pathways and DNA repair. Chk2 is a protein that
is stably expressed throughout the cell cycle and is acti-
vated in response to DNA-damage; in particular DNA
double-strand breaks through the ATM-Chk2-p53-p21
pathway. The expression of Chk1, on the other hand, is
primarily found in S- and G2 phases, where it is active
even in the unperturbed cell cycle. During normal cell
cycle progression, Chk1 has been shown to regulate
replication forks during DNA replication and entry into
mitosis. Chk1 activation in response to DNA-damage is
preferentially triggered through the ATR-Chk1-CDC25
pathway, although some cross-talk between Chk1 and
ATM has been reported (reviewed in [17]. Chk1 has
been shown to activate Wee1 in Xenopus extracts and
yeast; however such a relationship has not been recapit-
ulated in higher eukaryotes [18, 19]. Previous studies
have shown an advantageous effect of combining Wee1
and Chk1/2 inhibitors as compared to mono-targeting
in a variety of cancer cell lines, and points to comple-
mentary functions of the kinases [13, 20, 21].
In the present study we investigated the combined use
of the Wee1 inhibitor MK1775 with a Chk1/2 inhibitor
(AZD7762) in a panel of metastatic melanoma cell lines.
While both inhibitors had an effect as mono-agents,
combined administration gave a stronger anti-tumour ef-
fect both in vitro and in xenografts models. Co-treatment
led to increased dephoshorylation of CDK1, DNA-damage,
premature mitosis and apoptosis. In summary, our results
warrant further evaluation of combined use of Wee1 and
Chk1/2 inhibition in malignant melanoma.
Methods
Cell lines and growth conditions
The human metastatic melanoma cell lines WM239,
WM45.1, WM983B and WM1366 were kindly provided by
Prof. Meenhard Herlyn (the Wistar institute, Philadelphia,
USA) [22, 23]. The FEMX-1 cell line was established at the
Radium hospital [24]. The ‘Patient 3’ cell line was a kind
gift from Prof. Peter Hersey (Royal North Shore Hospital,
Sydney, Australia) [25]. All cell lines were maintained
in RPMI-1640 medium (LONZA, Verviers, Belgium)
supplemented with 5 % Fetal Calf Serum (Biochrom,KG, Berlin, Germany) and 2 mM L-glutamine (LONZA,
Verviers, Belgium). The cells were grown in culture at
37 °C in humidified conditions containing 5 % CO2, either
as monolayer cultures in 75 cm2 bottles or in 96
flat-bottom well plates. Normal human melanocytes
(FOMA4) and fibroblasts (FF144sc) were isolated from
human foreskin and cultured in 254CF (Invitrogen
corporation, CA, USA) and DMEM 10 % FBS medium,
respectively, as previously described [6].
Spheroids were generated by plating suspended cells
(500–4000 cells/well, dependent on the cell line) in
Corning® 96 Well Clear Round Bottom Ultra Low At-
tachment Microplates (Corning, MA, USA). Spheroid
formation was allowed for 3 days prior to treatment.
Images of spheroids were obtained using phase-
contrast on an Olympus IX81 microscope with a 4×
objective. Spheroid volume was calculated using Olym-
pus Soft Imaging Solution Gm6H software. A minimum
of two independent biological experiments were con-
ducted, where each experiment contained at least four
parallels of the individual treatment options.
Chemical inhibitors
Wee1 inhibitor MK1775 and Chk1/2 inhibitor AZD7762
were purchased from Selleck Chemicals (TX, USA) and
used for time intervals and concentration indicated in
the text.
Small interfering RNA (siRNA) transfection
All cell lines were plated in either 6-well plates (1.5 × 105
cells/well) or in 96-well plates (5 × 103 cells/well) 24 h in
advance of the transfection. The cells were transfected with
10nM siRNA targeting Wee1 (OligioID; ‘VHS50841’),
Chk1 (OligioID: ‘VHS40226’) or RNAi negative control
duplexes (Negative Control LOW GC, 12935–200)
using Lipofectamine™ RNAiMAX transfection reagents
(all reagents from Invitrogen corporation, CA, USA).
Transfection was allowed for 5 h before the medium
was replaced with RPMI w/5 % FCS and 2 mM L-
glutamine. Transfected cells were harvested after 48 h
for further analysis.
Viability assays
Four thousand cells per well were seeded in 96-well
plates and left to attach overnight, before treatment with
MK1775 and/or AZD7762 for 48 h. The growth inhibi-
tory effects of mono- and combined treatments were
measured using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
(MTS) assay (Promega, WI, USA). Absorbance was
measured at 490 nm using ASYS UVM340 96-well plate
reader. Alternatively, viability was assessed using the
CellTiter-Glo® Luminescent Cell Viability Assay kit (Pro-
mega) following the manufacturer's protocol. Luminescence
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Viability of treated cells was normalized to the untreated
control cells. Each experiment was performed with three
parallel observations and repeated at least three times.
Calcusyn analysis
Synergy was determined by the Chou and Talalay Com-
bination Index (C.I.) [26] for non-exclusive treatments
(treatments affecting different targets or sites of the same
target), and calculated by Calcusyn software (BioSoft,
Feruson, MO, USA). Of note, this method requires
that a dose effect curve for each drug is made, in
which the data-points give a good r-value (>0.90 for
cell systems) [27]. Given the variation in dose effect of
the drugs in the different cell lines, the concentrations
of the inhibitors were adjusted for the individual cell
lines (Additional file 1: Figure S1) in order to abide to
the requirements of the method.
Western blot analysis
Cells were harvested and western blot conducted as pre-
viously described [6]. Caspase 3 (#9662/#9664 (even
mix)), Caspase 8 (#9746), Caspase 9 (#9502), PARP
(#9532) and Wee1 (#4936S) primary antibodies were
purchased from Cell Signaling (Beverly, MA). α-tubulin
(DMIB) was acquired from Calbiochem (Nottingham,
UK), whereas Cyclin A (sc-751) and p53 (sc-126) anti-
bodies were obtained from Santa Cruz (Santa Cruz, CA).
γ-H2AX (#05-636) and pCDK1Tyr15 (ab47594) antibodies
were acquired from Millipore and Abcam (Cambridge,
England), respectively. Following primary hybridization,
membranes were washed 3 × 10 min in TBST and
hybridized with an appropriate secondary antibody (HPR-
conjugated anti-rabbit or anti-mouse IgG antibodies
(Promega)) for 1 h at room temperature, with gentle
agitation. Membranes were then washed in TBST for 3 ×
10 min before being incubated in ECL-plus (GE Health-
care, Chalfont St Gils, UK) for 5 min. Protein bands were
visualized by exposing the membranes to X-ray films.
Flow cytometry and barcoding
Cells were harvested by trypzination and fixated in 70 %
ice-cold ethanol at −20 °C for a minimum of 24 h. In
order to eliminate variation in antibody staining, control
as well as treated cells were labelled with different
concentrations of Pacific Blue (0.125, 0.031, 0.0062 and
0.00078 ng/μL, respectively) for 30 min at RT in the
dark, in accordance with the fluorescent cell barcoding
(FCB) technique [28]. All samples were subsequently
mixed in one tube and incubated with primary anti-
bodies (mouse anti-γH2AX (1:500, 05–636, Millipore)
and rabbit anti-phospho Histone H3 (ser10) (1:500,
CS#9701, Cell Signaling)) diluted in detergent buffer
(0.1 % Igepal CA-630, 6.5 mM Na2HPO4, 1.5 mMKH2PO4, 2.7 mM KCl, 137 mM NaCl, 0.5 mM EDTA
[pH 7.5]) containing 4 % nonfat milk for 1 h at RT, and
afterwards with secondary antibodies; anti-rabbit Alexa488
and anti-mouse Dyelight549 (1:1000, Invitrogen) for 30 min
at RT in the dark. Cells were finally incubated with PBS con-
taining Cell Cycle 633/Fx cycle™ far red stain (1 μL/mL,)
and PureLink RNAse A (5 μL/mL) (Invitrogen) for 30 min
at 4 °C in the dark. Flow cytometric analysis was performed
using a LSRII flow cytometer (BD Biosciences) with Diva
software, and the four samples were gated based on the
Pacific Blue signal before analyzes of cell cycle distribution,
γH2AX and phospho Histone H3 (ser10) expression.
In vivo studies
‘Patient 3’ cells (2 × 106) were subcutaneously injected
on each side of the dorsa of nude female mice (athymic
nude foxn1 nu) and tumour bearing mice were subse-
quently divided into groups of 7 mice each. MK1775
and AZD7762 were dissolved and administered as rec-
ommended by the manufacturer (Selleck Chemicals).
Briefly, 30 mg/kg MK1775 were given orally whereas
25 mg/kg AZD7762 were administered intravenously
both as single agents and in combination. The treat-
ments were given 3 times a week for 2 weeks. Control
mice received no treatment as we previously have ob-
served no effect of the vehicles alone. Tumour sizes were
measured regularly using a calliper, and the volume V
was calculated as follows: V =W2 × L × 0.5 (where W
and L are tumour width and length, respectively). The
experimental protocol was evaluated and approved by
the National Animal Research Authority and conducted
in accordance with regulations of the European Labora-
tory Animals Science Association.
Statistical analysis
All statistical analyzes were conducted using SPPS
PASWStatistics version 18. Comparison of tumour vol-
ume at day 48 was performed with one-way between-
groups ANOVA. Post-hoc comparisons were performed
using the Tukey HSD tests.
Results
Synergistic effect of combined treatment with Wee1
inhibitor MK1775 and Chk1/2 inhibitor AZD7762 in
melanomas
In order to study the effects of targeting Wee1 and Chk1/2,
a panel of six metastatic melanoma cell lines were treated
with increasing concentrations (0,063 μM to 1 μM) of the
commercially available inhibitors MK1775 (Wee1) and
AZD7762 (Chk1/2) for 48 h (Fig. 1a and b). Mono-
treatment with either inhibitor reduced the viability in
all tested cell lines, though the effect differed in a dose-
and cell line dependent manner. The most pronounced
effect was observed in WM45.1 (IC50: 0.4 μM (MK1775),
Fig. 1 Increased anti-tumour effect of combined inhibition of Wee1 and Chk1/2. a and b, Melanoma cell lines grown as monolayer cultures were
treated with increasing concentrations (0.063–1 μM) of MK1775 (a) or AZD7762 (b) for 48 h, and viability was measured by MTS analysis. c. Metastatic
melanoma cell lines and primary cultures of human melanocytes (FOMA4) and fibroblasts (FF144 SC) were exposed to 200nM MK1775 and/or 100nM
AZD7762 for 48 h. Cell viability was determined by MTS analysis. Data presented are the mean of at least three independent biological experiments
and presented with positive standard deviation
Table 1 The Combination Index (C.I.) values after combined
treatment with MK1775 and AZD7762






“Patient 3” 1.0 ±0.2
*C.I. values are estimated from the dose response effects presented in
Additional file 1: Figure S1A and 1B
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(MK1775), 0.04 μM (AZD7762)) cells. In the other cell
lines neither MK1775 nor AZD7762 were able to reduce
the viability by 50 % following treatment with concentra-
tions up to 1 μM of either drug (Fig. 1a and b).
We next investigated if combining the drugs could
further decrease the cell viability as compared to single-
agent treatments. The concentrations of the inhibitors
used for combinational studies were chosen to be within
the target-specific range of the compounds [29, 30].
While exposure to either 200nM MK1775 or 100nM
AZD7762 for 48 h only led to a modest reduction, co-
treatment resulted in a marked reduction in cell viability
(Fig. 1c). For WM983B cells, however, 100nM AZD7762
alone decreased the viability by 90 % and co-treatment
with MK775 did not enhance the effect. When reducing
the AZD7762 concentration, combined treatment with
MK1775 was superior to single-agent treatment also in
this cell line (Additional file 1: Figure S1). Of note, pri-
mary cultures of melanocytes (FOMA4) and fibroblasts
(FF144SC) were only modestly affected when exposed
to either mono- or combinational treatment (Fig. 1c).
Finally, in order to verify that the effect of the inhibi-
tors could be assigned to targeting Wee1 or Chk1 we
performed siRNA mediated knockdown of the proteins
in three of the cell lines (WM239, WM45.1, WM983B)
(Additional file 2: Figure S2A and 2B).
To further address the anti-tumour effect of combin-
ing the two inhibitors, drug interaction was determinedusing the Chou-Talalay method for quantifying synergy
or antagonism [26]. Co-treatment with different concen-
trations of MK1775 and AZD7762 resulted in Combin-
ation Index (C.I.) values of less than 1 in the majority of
cases, indicating a synergistic interaction of the drugs
(Table 1 and Additional file 1: Figure S1).
Together, our results demonstrate an increased anti-
tumour effect of co-targeting Wee1 and Chk1/2 in melan-
oma cell lines.
Combined inhibition of Wee1 and Chk1/2 leads to
reduced viability and irreversibly inhibits growth of
melanoma 3D-cultures
Three-dimensional tumour cell cultures have in several
studies been reported as superior to monolayer cultures
in terms of reflecting in vivo conditions for testing drug
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aim was to study long-term effects of MK1775 and
AZD7762 on cells grown as spheroids (3D-cultures).
Cells cultured as spheroids for 3 days were exposed to
200nM MK1775 and/or 100nM AZD7762 for a total of
3 days, and followed for an additional 8 days (Fig. 2a).
During the latter period, 50 % of the medium was re-
placed twice with drug-free medium. Whereas spheroids
given mono-treatments appeared diminished on day 14,
combinational inhibition led to a marked decrease in
spheroid size (Fig. 2b and d). Moreover, daily monitoring
of growth revealed that WM45.1 and WM983B spher-
oids treated with the drug combination were unable to
expand in size following drug-removal, thus indicating
an irreversible effect within the time-frame of theFig. 2 Cytotoxic effects of MK1775 and AZD7762 are not reversed by med
was allowed prior to treatment (day 0–3), inhibitors (MK1775: 200nM, AZD7
medium was substituted by fresh medium containing no inhibitors. b. Sph
in bottom right corners show 500 μm. c. Spheroid viability was estimated b
four individual experiments. d. Spheroid volume (Y-axis) was measured/esti
in volume were estimated for each spheroid relative to its size on day 3. The
with positive standard deviationsexperiment (Fig. 2d). The volume of the WM239 spher-
oids, however, continued to increase following treat-
ment, but remained markedly reduced compared to the
control. In consistence with this, cell viability estimated
by CellTiterGlo assay on day 14 was greatly reduced in
spheroids treated with the drug-combination in contrast
to those in the control or mono-treatment groups
(Fig. 2c). In accordance with our observation in 2D
models, the decrease in viability following combinational
treatment was more profound in WM45.1 and WM983B
spheroids, as compared to WM239 cells. Together, our
results indicate that combined use of MK1775 and
AZD7762 has an increased anti-tumour effect compared
to mono-treatment also in 3D cultures, and prevents
spheroid growth even after drug-removal.ium renewal in 3D cultures. a. Experiment outline; spheroid formation
762: 100nM) were added on day 3. On day 6 and 10 50 % of the
eroids were visually assessed on day 14 using light microscopy; scales
y CellTiterGlow analysis on day 14, and presented as the average of
mated using Olympus Soft Imaging Solution Gm6H software. Changes
graphs represent the average of two individual experiments presented
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melanoma xenografts
Based on the promising in vitro results, we next investi-
gated the in vivo efficacy of treatment with MK1775 and
AZD7762 in melanoma xenografts. For this study we
chose a cell line named ‘Patient 3’, that was recently
established from a metastasis from a patient undergoing
treatment with the selective BRAF inhibitor PLX4720,
and previously DTIC [25]. Mono-treatment with either in-
hibitor resulted in reduction of tumour sizes as compared
to the control group, and a tendency to a more prominent
effect in the group given a combination of the two drugs
was observed (Fig. 3). A statistically significant difference
(p < 0.05) in tumour volume was found by ANOVA. Post-
hoc comparisons using the Tukey HSD test indicated that
the mean score of the control group (M= 14.47, SD =
2.87) was significantly different (p < 0.024) from the com-
bination group (M= 6.47, SD = 3.88). No direct immediate
toxic effects were observed during the experiment with
the given dosages.
Inhibition of Wee1 and Chk1/2 lead to DNA-damage and
apoptosis
To elucidate the mechanisms by which MK1775 and
AZD7762 affect melanoma cell viability, we first examined
the effect on Tyr15 phosphorylation of CDK1 in WM239,
WM45.1 and WM983B cells after being exposed to
200nM MK1775 and/or 100nM AZD7762 for 48 h.
Whereas Wee1 inhibition decreased pCDK1 expression in
all cell lines, the combination of drugs resulted in an even
stronger reduction, as assessed by western blot analysis
(Fig. 4a). Down-regulation in pCDK1 expression following
treatment was also observed after shorter exposure times
(1, 3, 7 and 24 h, data not shown). Interestingly, treatmentFig. 3 Combinatorial treatment with MK1775 and AZD7762 reduces
tumour growth in melanoma xenografts. “Patient 3” xenografts were
treated with MK1775 (30 mg/kg, three times per week, orally), AZD7762
(25 mg/kg, three times per week, i.v. injection) or a combination of
theinhibitors, for two weeks (7 mice per group). The tumour volumes
were measured twice a week using a caliper, and are presented as
tumour volume relative to the volume of the tumour at the initiation of
the treatment. Standard bars represent positive standard deviation.
Comparison of tumour volume at day 48 was performed with one-way
between groups ANOVA, and post-hoc comparisons with the Tukey
HSD tests (*p< 0.024 untreated vs. combination group)with the Chk1/2 inhibitor, alone or in combination with
Wee1 inhibition, decreased the total level of CDK1 in
WM983B cells. Similar patterns were observed following
siRNA transfections targeting Wee1 and Chk1, although
combinational treatments with siRNA had less effect than
what was observed with the inhibitors (Additional file 2:
Figure S2C).
Furthermore, as seen in all three cell lines, both mono-
and combinational treatment, as well as siRNA mediated
knockdown, led to increased expression of γ-H2A.X,
indicative of DNA double-strand breaks [34] (Fig. 4a
and Additional file 3: Figure S3C). A further increase in γ-
H2A.X was observed in WM239 cells following combined
targeting of Wee1 and Chk1/2, as opposed to treatment
with either inhibitor alone. Cleavages of Caspase 3 and
PARP, associated with apoptosis, were observed in all
three cell lines following treatment with the inhibitors.
Combined inhibition led to a more pronounced cleavage
product when compared to either single agent treatment,
as assessed by immunoblotting (Fig. 4a). These findings
indicate that simultaneous targeting of Wee1 and Chk1/2
leads to DNA-damage and apoptosis in melanoma cell
lines.
Wee1 and Chk1/2 inhibitors induce premature mitosis
and DNA damage in S-phase cells
To study how MK1775 and AZD7762 affect cells in dif-
ferent phases of the cell cycle, treatment with the re-
spective drugs were allowed for three hours (Fig. 4b–e
and Additional file 3: Figure S3). The short time frame
serves as a compromise between allowing the drugs to
work, while at the same time limiting cell cycle progres-
sion. Cells in different phases of the cell cycle were gated
based on their relative amount of DNA and expression
of the mitotic marker phospho-Histone H3 (pHH3), as
analyzed by flow cytometry (Fig. 4b). Narrow gating for
cells belonging to G1, S and G2 were used in order to
avoid incorrect/uncertain assumptions of which cell
cycle phase a cell belongs to (Additional file 3: Figure
S3). Higher drug concentrations (2 μM MK1775/1 μM
AZD7762) were used given the short exposure time,
(Fig. 4b–e), however the same trends were also observed
following treatment with lower doses of MK1775 (200nM)
and AZD7762 (100nM) (Additional file 4: Figure S4).
Whereas exposure to either inhibitor led to an increased
amount of mitotic cells, this fraction was augmented by
the drug combination. Moreover, combined treatment led
to an increased fraction of S-phase cells co-expressing
pHH3, indicative of cells having entered mitosis prema-
turely (Fig. 4b, c and Additional file 4: Figure S4).
To further study how the inhibitors affect cells in differ-
ent phases of the cell cycle, we examined the median
expression of γ-H2A.X in the gated sub-groups (Fig. 4c,
(for gating of cells, see Additional file 3: Figure S3))
Fig. 4 Combined inhibition of Wee1 and Chk1/2 leads to increased mitotic entry and DNA-damage in S-phase cells. a. Cells were treated with
MK1775 (200nM) and/or AZD7762 (100nM) for 48 h. Expression of proteins involved in DNA-damage response and apoptosis was determined by
western blot analysis, and α-tubulin was used as loading control. b, c, d and e. WM983B cells were treated with either DMSO (control) or high
concentrations of MK1775 (2 μM) and/or AZD7762 (1 μM) for 3 h, and analyzed by Flow Cytometry B. Subpopulation gating of mitotic (blue) and
pre-mitotic (purple) cells were based on their DNA content and expression of pHH3. The percentages of cells are indicated above the gated
populations. c. The percentage of cells in mitosis (M) and pre-mitosis (Pre-M) are shown as fold change from the control cells. d. Expression of
γ-H2A.X, indicative of DNA-damage, was assessed following treatment with inhibitors. e. The median expression of γ-H2A.X was determined
for cells in the indicated phases of the cell cycle (for gating see Additional file 3: Figure S3), and shown as fold change from the control cells.
Data are representative or average of four independent experiments
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and e, increased expression of γ-H2A.X was predomin-
antly found in S-phase cells, indicating that cells undergo-
ing DNA-replication are especially sensitive to DNA-
damage. Our results therefore suggest that combined
treatment with MK1775 and AZD7762 leads to premature
mitosis and DNA-damage in S-phase cells.
Discussion
In our previous study we showed that high expression of
Wee1 is associated with poor disease-free survival in pa-
tients with melanoma and that in vitro targeting of the
kinase leads to decreased cell viability. To further evalu-
ate Wee1 as a potential target in melanoma, we have in
the present study combined a Wee1 inhibitor (MK1775)
with a Chk1/2 inhibitor (AZD7762). Our hypothesis isthat simultaneous inhibition of two cell cycle control
proteins will introduce a high degree of DNA-damage
incompatible with cell viability. The combined inhibition
led to an increased anti-tumour effect both in vitro and
in xenografts models. Furthermore, our in vitro studies
showed that co-treatment synergistically decreased via-
bility and increased apoptosis, which may be explained
by DNA-damage- and premature mitosis of S-phase
cells. Our results provide a rationale for further testing
of the treatment regimen in melanoma models.
Mono-targeting of Wee1, either by siRNA mediated
knockdown or inhibitors, has shown a potent anti-
tumour effect in some cancer cell lines [6, 35] but only
limited effect in other studies [7, 8]. In line with this, the
efficacy of mono-targeting of Wee1 by MK1775 varied
in the tested melanoma cell lines in the present study,
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some of the cell lines, such as WM1366. Interestingly, a
stronger anti-tumour efficacy was observed in the same
cell line following exposure to MK1775 in a recent study
by Haarberg et al. [36], however the experimental condi-
tions in our studies differ with regard to exposure time
to the drug and assay for detecting viability.
For the purpose of increasing the efficacy, inhibition of
Wee1 (MK1775) has been combined with other thera-
peutic agents in clinical trials, such as gemcitabine and
cisplatin [ClinicalTrials.gov]. Simultaneous inhibition of
Wee1 and Chk1, on the other hand, has only been inves-
tigated in preclinical studies, but has been found as an
eligible combination following siRNA high-throughput
screens of acute myeloid leukemia, lung-, prostate- and
ovarian cancer [13, 20, 21]. Combined inhibition of
Wee1 and Chk1 using commercial inhibitors have been
shown to synergistically enhance the therapeutic efficacy
in several cancer cell lines, including the A2058 melan-
oma cell line [13, 16, 20, 37]. In agreement with these
reports, combined targeting of Wee1 and Chk1/2 led to
a synergistic reduction of viability in our cohort of
melanoma cell lines. In addition, the same trends were
observed for combined siRNA mediated knockdown of
Wee1 and Chk1 compared to mono-targeting of either
protein. However, siRNA mediated down-regulation and
use of small molecular inhibitors are not always compar-
able [21]. The experiments using siRNA only targeted
Chk1, whereas AZD7762 inhibits both Chk1 and Chk2.
Still, a previous study by McNeeley et al. showed that
the anti-tumour activity of AZD7762 following DNA
damage is likely related to Chk1- rather than Chk2 in-
hibition [38].
Similar to what was observed in monolayer cultures,
an increased effect of combined targeting was also found
in multicellular spheroids. Likewise, a weak increase in
efficacy was observed in melanoma xenografts following
combined treatment versus either mono-treatment
alone. A previous study showed that combinational
inhibition of Wee1 (MK1775) and Chk1 (MK8776) led
to increased in vivo efficacy in neuroblastoma xenografts
[39], providing additional support for our results.
Studies have indicated that the response to Chk1 or
Wee1 inhibitors is dependent on the p53 mutational
status of the cells, in particular when combined with
DNA-damaging agents, while others have reported no
such effect [40, 41]. Partly supporting the first hypoth-
esis, the anti-tumour effect was most pronounced in
the p53 mutated WM983B and WM45.1 cells, and less
in the p53WT cell line WM239. Although disabling
point mutations in TP53 are only found in 10 % of mela-
nomas, inactivation of the protein is found in approxi-
mately 90 % of the tumours (reviewed in [42]), suggesting
that the effect of checkpoint inhibition in melanoma is notstrictly dependent on the p53 mutation status. Further-
more, the level of genetic instability has been suggested as
a predictor of the response to Wee1 and Chk1/2 inhibition
[43, 44]. In this regard, melanomas have been shown to be
one of the most genetically unstable tumour forms [45, 46].
Combined inhibition of Wee1 and Chk1/2 in primary cul-
tures of melanocytes or fibroblasts had less effect on viabil-
ity than observed in the melanomas. In accordance with
these results, Carrassa et al. found no synergistic effects of
combining Wee1 (MK1775) and Chk1 inhibitors PF-
00477736 (or allegedly AZD7762) in the normal fetal
human lung cell line MRC-5 [20]. While both Wee1 and
Chk1 are known to have functions in the unperturbed cell
cycle, normal cells are less proliferative and have a lower
degree of genetic alterations- and instability than tumour
cells, which may explain the difference in response to
kinase inhibition. However, phase I clinical trials with
AZD7762 have been terminated due to cardiac toxicity
in patients [47, 48], and also clinical trials with other
Chk1 and Chk1/2 inhibitors (reviewed in [49]) have been
terminated. Concerns have been raised on whether target-
ing Chk1 may lead to toxicity in normal cells due the
multiplicity of functions of the protein in the unperturbed
cell cycle (Reviewed in [50]). Furthermore, embryonic le-
thality is associated with Chk1 depletion in mice [51]. On
the other hand, the observed toxicities in patients follow-
ing treatment with various Chk1 inhibitors have appeared
as drug-specific rather than class-specific and may thus be
a consequence of off-target effects (reviewed in [49]). Clin-
ical studies with novel Chk1 (MK-8876/SCH 900776) and
Chk1/2 (LY2606368) inhibitors with improved specificity
are currently ongoing or recruiting (ClinicalTrials.gov).
When further investigating the effect of combined inhib-
ition of Wee1 and Chk1/2, we found a stronger reduction
in pCDK1 (tyr15) levels compared to treatment with
either drug alone. In line with this, Wee1 has been
shown to directly phosphorylate CDKs, and removal of
Wee1 is thus expected to reduce such phosphoryla-
tions [52]. Chk1, on the other hand, phosphorylates
the CDC25 phosphatases, leading to the latter proteins
sequestration or degradation, thereby hindering acti-
vating dephosphorylation of pCDK1/2 (tyr15) [53].
CDK1/2 phosphorylation is thus indirectly maintained
by Chk1, and removal of the latter may promote fur-
ther reduction of pCDK1/2. Inhibition of Wee1 and
Chk1 has previously been shown by Davis et al. to be
accompanied by decreased expression of pCDK1 and a
synergistic reduction in cell viability [13]. They further
showed that the antiproliferative effect of the inhibitors
was partially reversed after CDK inhibition (Roscovitine),
suggesting that CDK hyperactivity may be a contributing
factor, rather than the sole cause of the antiproliferative
effect of Chk1 and Wee1 inhibition. Deregulated activity
of CDKs, as a consequence of Wee1 depletion, has in a
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loss of genomic integrity through subsequent nucleotide-
shortage and increased firing of replication origins [54]. In
line with this, we observed that inhibition of Wee1 led to
increased levels of DNA-damage and apoptosis, as assessed
by expression of γ-H2A.X and cleavage of caspase 3 and
PARP, respectively. The effect on apoptosis was amplified
by combining the inhibitors, supporting a synergistic effect
on viability. A further increase in DNA-damage following
combined targeting of the kinases was seen in WM239
cells. Similarly, combined inhibition of Wee1 and Chk1
has in a previous study been demonstrated to induce a
more intense and durable DNA-damage and anti-tumour
effect than either drug alone [37]. Interestingly, treatment
with the Chk1/2 inhibitor or Chk1 siRNA reduced the
total protein level of CDK1 in the WM983B cell line.
In agreement with this, transcriptional reduction of
cell-cycle regulators, such as CDK1, has been observed
after Chk1 depletion in somatic cells [55].
Similar to what has been reported by others [37, 56, 57],
inhibition of Wee1 as well as Chk1 was shown to induce
DNA-damage in the S phase of the cell cycle. These find-
ings are in accordance with the proposed function of the
kinases in restraining CDK activity during DNA replica-
tion (reviewed in [58]). Furthermore, it has been suggested
that the cytotoxic effect of Chk1 inhibition in melanoma
cells is most likely due to inhibition of Chk1 in S phase,
which drives cells prematurely from late S phase into an
aberrant mitosis [43]. In line with this, combinational
treatment with Chk1/2 and Wee1 inhibitors increased the
population of S-phase cells co-expressing the mitotic
marker, pHH3. These are cells that have entered mitosis
without having completed replication, most likely due to
the compromised G2/M checkpoint in the absence of
Wee1 and/or Chk1. Likewise, an increased proportion of
mitotic cells was observed following mono-targeting, and
to a further extent by the combination of the inhibitors.
Most likely the G2 cells have abrogated the G2/M check-
point and entered mitosis given the short timeframe of
this experiment (3 h).
Conclusions
In summary, our results support an increased anti-tumour
effect of combined inhibition of Wee1 and Chk1/2 and
provide a rationale for further evaluation of the kinases as
therapeutic targets in human melanomas.
Additional files
Additional file 1: Figure S1. Synergistic effect of combining Wee1
and Chk1/2 inhibitors. A . Cells were treated with three different
concentrations of MK1775 (200, 400 and 800nM) and/or AZD7762
(50, 100 and 200nM) as indicated. Cell viability was measured by MTS
after 48 h. B. The combination Index (C.I.) values were calculated byCalcuSyn software based on the Chou Talalay method for measuring
drug interaction, for each combination of inhibitors C and D. Drug
concentrations were adjusted for WM983B (MK1775; 50, 100 and
200nM and/or AZD7762 (20, 40 and 80nM) and WM1366 (MK1775; 1, 2
and 4 μM and/or AZD7762 (0.25, 0.5 and 1 μM) cells in order to abide
to Chou Talalay method requirements. Data are the mean of three independent
experiments and presented with error bars showing positive standard deviation.
Additional file 2: Figure S2. Increased anti-tumour effect of SiRNA
mediated knock-down of Wee1 and Chk1. A and B. Cell viability was measured
48 h following SiRNA mediated knockdown by MTS (A) and CellTiterGlow (B)
assays. C. Expression of proteins involved in DNA-damage response and
apoptosis was determined by western blot analysis, and α-tubulin used
as loading control. Data are the mean or representative of three
independent experiments.
Additional file 3: Figure S3. Example of sub-gating of cells in different
phases of the cell cycle. Different samples (Control, MK1775, AZD7762,
Combination) were separated by their relative expression of Pacific blue
(See Methods for barcoding procedure). Cells of different phases of the
cell cycle were sub-gated based on DNA content and expression of the
mitotic marker pHH3 (dark green: G1, Blue: S, orange: G2 and purple:
Mitotic cells). Median expressions of γ-H2A.X were determined by Diva
software.
Additional file 4: Figure S4. Combined inhibition of Wee1 and Chk1/2
leads to increased mitotic entry and DNA-damage in S-phase cells.
Cells were treated with indicated concentrations of MK1775 (MK) and
or AZD7762 (AZD) for 3 h, barcoded and analyzed by flowcytometry.
A. Percentage of cells in mitosis (M) and pre-mitosis (Pre-M) were calculated
relative to the control. B. Median expression of γ-H2A.X in cells of different
cell-cycle phases, relative to the control. Data are the mean of four
independent experiments.
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